Lormalzi (donanemab) launched in India as a disease-modifying Alzheimer's therapy targeting amyloid plaques The treatment suits patients with mild cognitive impairment or mild dementia with confirmed amyloid pathology Therapy not recommended for advanced dementia, brain bleeding risk, or severe vascular conditions